Health Check: On Lamington Day, biotechs serve up their chocolate-dipped quarterly morsels
Amplia to raise capital after runaway share performance
Tryptamine starts binge eating 'magic mushie' trial
Today is National Lamington Day and biotechs are serving up a solid sponge-like base of news encased in chocolate and coconut – occasionally interspersed with a jam layer.
Hold the cream and pink jelly though – it just doesn't work.
Like so many drug discoveries, the lamington had serendipitous origins.
The story goes that one of Queensland governor Lord Lamington's maids was serving up a yellow sponge, but accidentally dunked it into molten chocolate.
Lord Lammo recommended the squares to be rolled into coconut shavings for ease of eating – and the rest is history.
As is this non-sequitur. Now onto the biotech news.
Lumos glows after last week's mega deal
Point-of-care diagnostics house Lumos Diagnostics (ASX:LDX) reports revenue of $12.4 million for the year to June 30, up 12%.
June quarter revenue declined 26% to $2.6 million, owing to the end of the US flu season.
Lumos reported cash outflows of US$1.7 million for the quarter, taking June 30 cash to US$2 million.
Investor interest has focused on last week's mega US distribution deal with Phase Scientific, which could deliver Lumos up to US$317 million ( $487 million) over six years.
This pertains to the company's bacterial-versus-viral rapid lateral flow test, Febridx.
Lumos has also signed a term sheet for a $5 million loan facility, proffered by shareholders Tenmile Ventures (Andrew Forrest) and Ryder Capital.
At its discretion, Lumos can draw down the facility over the next 12 months.
Cleo eyes FDA approval for ovarian cancer assay
Still on diagnostics, Cleo Diagnostics (ASX:COV) says it aims to submit a US Food & Drug Administration (FDA) marketing approval application for its ovarian cancer assay next year.
The company is on track to complete a supportive US trial in the December quarter.
Thanks to government grants and tax incentives, Cleo reported cash inflows of $38,000, taking end of quarter cash to $6.46 million.
Turning to drug development, genetic disease specialist PYC Therapeutics (ASX:PYC) reports cash outflows of $17.6 million. At quarter's end the company still had cash of $153 million.
The company has dosed the first patient in a combined phase 1a/2b trial for polycystic kidney disease.
PYC has achieved 'alignment' with the FDA on the structure of a registrational trial for its lead program, the blinding eye disease retinitis pigmentosa type 11.
The company believes the regulator will require only a phase II trial.
Tryptamine BEDS down eating disorder trial
Psychedelic medicines house Tryptamine Therapeutics (ASX:TYP) has started recruiting patients for a world-first binge eating disorder (BED) study.
In the open-label trial, 12 patients will be administered intravenously infused psilocybin, combined with psychotherapy.
Melbourne's Swinburne University is undertaking the study, with first dosing this quarter and top line results due by the end of the year.
BED is the most common eating disorder in the US and second most prevalent in Australia here.
The condition can result in depression, anxiety, post-traumatic stress disorder and compulsive behaviour.
Amplia passes the hat
Meanwhile Amplia (ASX:ATX) shares this morning entered trading halt, ahead of a share placement and share purchase plan.
Amplia thus continues the rich tradition of companies leveraging clinical trial results, in this case its stunning data for hard-to-treat pancreatic disease.
Amplia has reported 17 'partial response' rates in it Accent trial, in 17 out of 55 advanced disease patients.
A confirmed partial response is tumour shrinkage of more than 30%, sustained for two or more months with no new cancerous lesions detected.
Amplia is testing AMP-945 (narmafotinib). AMP-945 appears to inhibit the protein FAK, which is overexpressed in pancreatic cancers.
Amplia shares have surged 376% in the past 12 months, but investors still value the company at a modest $110 million.
As of the end of March, Amplia had cash of $10.8 million.
'Perplexed' Imugene laments soft-as-a-sponge share price
Imugene (ASX:IMU) chairman Paul Hopper hopes the company's lamington-soft share price will 'do an Amplia' (our words) and reflect the company's progress with its multiple cancer trials.
The company last Monday announced its phase 1b study for an aggressive blood cancer had resulted in two additional 'complete responses' (that is, the tumours disappeared).
Imugene is trialing Azer-cel, its allogeneic Car-T drug made from healthy donor T-cells rather than the patient's.
Naturally, Imugene announced a $22.5 million and share purchase plan for up to $15 million.
On reinstatement, the shares lost 4.5 cents, or 10%, taking the loss over the past year to around 80%. This allows for a one for 34 share consolidation.
'We are very disappointed with the share price performance,' Hopper says.
'We are perplexed why we had such a lukewarm reception to the earlier data at the start of year.'
Cashed up for pivotal trial
But with the share raising in train, Imugene investors should no longer fear that such a dilutionary event is around the corner.
Post raising Imugene should have cash of $64 million, with management costing a 60-80 patient pivotal trial at $30-40 million.
If approved, Azer-cel would be the first commercial allogenic Car-T treatment, enabling mass produced, off-the-shelf therapies.
'We are in active discussions with partners on the strategy for developing the drug and getting it approved,' Hopper says.
Shares settle in orbit after last week's Meso-blast off
Mesoblast (ASX:MSB) shares have taken a breather after Friday's 35% surge on the back of initial US sales of its first US-approved stem cell product.
The company reported unaudited June quarter revenue of US$13.2 million ($20.3 million) for Ryoncil, its treatment for childhood graft-versus-host disease.
The FDA approved Ryoncil in December last year.
Mesoblast founder and CEO Prof Silviu Itescu points to higher sales in the current quarter, given US Centres for Medicare and Medicaid Services coverage became effective on July 1.
The company has signed up more than 25 transplant centres and hopes to enlist all 45 priority centres by October.
Bell Potter analyst John Hester says the sales were in line with the firm's expectations.
'The figure is inclusive of sales to the distributor, nevertheless it represents a reasonable proxy for hospital demand.'
The firm values Mesoblast at $3.50 a share, implying 55% of upside.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
12 minutes ago
- News.com.au
Greens to continue calls for Labor to end capital gains tax at Economic Reform Roundtable
The Greens will continue their campaign to end capital gains tax concessions and negative gearing, as the diminished party looks to rebuild after an electoral disaster which resulted in the loss of former leader Adam Bandt and two other MPs. The minor party holds just one seat in the House of Representatives, with Ryan MP Elizabeth Warren-Brown clinging onto her Brisbane seat despite a 5.2 per cent swing to Labor, while maintaining 11 seats in the Senate. However, ahead of Labor's Economic Reform Roundtable in August, new party leader Larissa Waters said the party would continue to advocate for negative gearing and capital gains tax concessions to be scrapped. The benefits gives property investors to only pay tax on 50 per cent of the profit made from the sale, with the Greens arguing that it increases property demand and 'turbocharges housing inequality'. The policy was a key plank of the Greens unsuccessful election policy, which saw Mr Bandt, party housing firebrand Max Chandler-Mather and Stephen Bates ousted. 'On housing, we know that there is so much more that the government needs to do in this term and we won't stop pushing for an end to negative gearing and unlimited rent increases,' Senator Waters said. 'Getting changes to CGT discount would demonstrate the government's willingness to fight for renters and first homebuyers, not rich property investors.' While Anthony Albanese has repeatedly rejected changing the current settings, he faces opposition from rank-and-file members calling on a revision of the tax. Grassroots advocacy group Labor for Housing has repeated calls for reform, stating the cost of the concession – about $20bn a year – should be redirected to public housing projects. However the Coalition has seized on Labor after accidental Treasury advice urged Treasurer Jim Chalmers to consider increasing taxes to fix the budget deficit, with Sussan Ley vowing to fight against any new taxation plans. Alongside scrapping the tax concession, the Greens have also called for tax breaks for new mums re-entering the workforce and the removal of fossil fuel subsidies and tax breaks for gas exporters. Complicated measures such as the family tax benefit, childcare subsidies and taxes can reduce the amount of take-home pay working mums are able to receive, with women sometimes left worse off when they transition to working to four or five days a week. Senator Waters said parents should be 'encouraged' to return to work, and not be 'smashed by tax so hard they're essentially working for free'. 'When a second parent goes back into the workforce, they can face an effective marginal tax rate of up to 80 per cent which punished mother for wanting to go back to work and perpetuates gender based economic disadvantage which haunts mothers for life,' she said. 'Right now, the government gives better tax incentives to investors like Clive Palmer or Gina Rinehart than it does to people who actually work for a living'.
The Australian
an hour ago
- The Australian
StockTake: Cannindah Resources
Stockhead's Tylah Tully cracks into Cannindah Resources (ASX:CAE) and the identification of its potential to substantially increase the amount of copper at its Mt Cannindah project in Central Queensland. An evaluation of historical data and recent surface mapping and sampling pointed towards potential extensions of the Cannindah Breccia resource, and features both in and outside the current resource controlling the locations of high-grade copper are now presenting fresh targets for a next round of drilling. Watch the video to learn more. This video was developed in collaboration with Cannindah Resources, a Stockhead advertiser at the time of publishing. This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Daily Telegraph
an hour ago
- Daily Telegraph
'The way I gasped!' Aussies gobsmacked over Gen Z's way of doing their tax returns
Don't miss out on the headlines from Lifestyle. Followed categories will be added to My News. A Gen Zer has left older Aussies gobsmacked after revealing how she submitted her tax return this year. In a revelation that would blow the mind of any Baby Boomer, Melbourne woman Paije recently divulged that she does her taxes each year using nothing but her smart phone. 'I just saw a video on my for you page where they were talking about that thing where some purchases you can do on your phone but big purchases have to be on your laptop,' the 28-year-old explained. 'I would like everyone to know that I did my taxes on my phone. I do everything on there.' Want to join the family? Sign up to our Kidspot newsletter for more stories like this. The 28-year-old worker received a lower tax return than previous years. Picture: @princesspeeny/TikTok For more stories like this, visit: Everything is on the phone The laptop Vs phone debate has gained traction in recent years. For Gen Zers who grew up as digital natives, they wouldn't think twice about making big purchases or completing in-depth tasks on their phone. For Millennials and other generations, things they consider 'major' tasks, such as purchasing a plane ticket, are reserved for the laptop, with the idea of being left with nothing but their mobile enough to send them into a panic. So, when Paije made her tax return confession, there were plenty of older Aussies who couldn't comprehend how she could complete such a significant task without whipping out her laptop. 'The way I gasped. Not on your phone,' one person said, with another joking, 'this feels illegal'. 'I didn't think anything at tax time could be worse than people saying getting a return just means you paid too much during the year, then I saw this,' another said. One person branded it 'criminal', adding that flights, tax and online furniture shopping are all laptop tasks. Another added: 'No way, that's definitely a desktop job.' However, there were plenty of people who saw no issue with it, with others claiming it is easier to do your taxes on your phone, particularly if you use the ATO app. 'I haven't opened my laptop since high school in 2019, I use my phone for everything,' one person said. Speaking to Paije said she wanted to tap into the running joke that older generations think some activities should only be done on laptops. 'I suppose I fall into that more Type B personality type and my attitude is that a phone is just a mini computer now,' the 28-year-old said. She also noted that the ATO's myDeductions app has become increasingly user friendly, making it really easy to do your tax return with nothing but your phone. In another video, Paije revealed she was getting a $921 refund after submitting her tax return, a figure she says is the 'worst' she has ever received. While the young worker understands that getting a smaller or no return means you have paid the correct amount of tax throughout the year, she noted that 'it still hurts'. In previous years, after submitting the same kind of deductions she did this year, her return would be in the $1500 to $2000 range. She also touched on her increasing HECS-HELP debt, which is currently sitting at almost $92,000. On June 1, indexation of 3.2 per cent was applied to all student loan debts. RELATED: Easy way to minimise the amount of tax you pay Paije said doing your taxes on your phone is a lot easier than people think. Picture: ATO Hecs and tax - what students need to know While there have been welcome changes to the way indexation occurs, with the lower of either the Consumer Price Index (CPI) or the Wage Price Index applied, there is still a lot of contention around the process. While payments towards your HECS debt are taken out of your pay in real time, that money is not coming off your debt at the same rate. Instead, the ATO holds these funds as a credit until you file your tax return on or after July 1. But, because indexation occurs before this on June 1, your past contributions are actually applying to the higher indexed rate, despite coming out of your pay much earlier. Because of this, many people with student loans feel like they will never see their debts reduce. 'The indexation from the last few years means that you're not really paying anything off because it just gets added again,' Paije said. She has two bachelors degrees and is currently doing her Masters and says the idea of paying off the debt doesn't even cross her mind anymore. 'I don't see it ever happening and so the best thing to do it just ignore it. Since the payments come out of my pay each fortnight I never see the money anyway, so I am kind of just choosing peace and pretending it doesn't exists,' she said. 'It would be too much mental effort that I don't have to care about it.' Originally published as 'The way I gasped!' Aussies gobsmacked over Gen Z's way of doing their tax returns
